FYR Diagnostics is at the forefront of transforming healthcare through innovative diagnostic solutions, particularly focusing on liquid biopsies. The company harnesses the unique properties of Extracellular Vesicles (EVs), which are membrane-enclosed nanoparticles released by cells that carry vital molecular information, including RNA and proteins. By utilizing EVs, FYR Diagnostics aims to develop next-generation biomarkers that can accurately reflect the molecular status of cells, thereby enhancing disease detection and monitoring. This approach offers a minimally invasive alternative to traditional surgical biopsies, making it easier to identify a wide range of diseases.

In addition to their focus on EVs, FYR Diagnostics employs a multiomics strategy through their EVO-Platform™, integrating data from genomics, transcriptomics, and proteomics to unlock the full potential of EVs. The company is also advancing proprietary technologies, such as Selective Protein Affinity Reagent Chemistries (SPARCs™), which facilitate the isolation of disease-associated EV subpopulations. This innovative targeting technology enhances the identification of biomarkers, improving patient stratification and increasing the likelihood of early disease detection. Through these cutting-edge technologies and a commitment to collaboration, FYR Diagnostics is poised to lead the next generation of diagnostic innovations.

United States

We believe in being a catalyst to transform healthcare.

We transform healthcare by developing diagnostic solutions that utilize novel insights on disease to innovate the next generation of liquid biopsies. We bridge the gaps between healthcare, patients, and disease.

FYR Diagnostics

Company Details